Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LauT-1 in Advanced Melanoma and Sarcoma
NCT06889766Phase 1Recruiting
- Sponsor
- Lausanne University Hospital
- Start
- Mar 2025
- Primary completion
- Jun 2029
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LauT-1 in melanoma and sarcoma, sponsored by Lausanne University Hospital. Primary endpoints: Incidence of treatment emergent adverse events at 90 days, Rates of production failure and drop-outs before infusion at 9 weeks and 1 more. Started Mar 2025; status: recruiting.
02
Drugs
LauT-1
03
Conditions
melanomasarcoma
Beyond the preview
Go deeper on NCT06889766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06889766.